Dutch regulators have signed off on AXIM Biotechnologies’ clinical trial plans for a chewing gum that offers controlled release of cannabinoids to treat multiple sclerosis patients’ pain and spasticity. The Dutch Medicines Evaluation Board’s sign-off on MedChew Rx means AXIM can start trials. A leader in … Read More
The post Holland Approves Clinical Trial Plans for AXIM’s Cannabis-based Gum for MS Pain and Spasticity appeared first on Dagga Magazine.